AVTX
Avalo Therapeutics Inc
NASDAQ: AVTX · HEALTHCARE · BIOTECHNOLOGY
$13.20
+2.64% today
Updated 2026-04-29
Market cap
$317.21M
P/E ratio
—
P/S ratio
5,376.53x
EPS (TTM)
$-5.84
Dividend yield
—
52W range
$3 – $21
Volume
0.8M
Avalo Therapeutics Inc (AVTX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-9.29M | $-11.49M | $-15.52M | $-10.16M | $-14.57M | $12.52M | $-3.13M | $-19.13M | $-40.54M | $-70.89M | $-26.75M | $-30.68M | $-49.06M | $-51.46M |
| Capital expenditures | $12432.00 | $29268.00 | $19502.00 | $19984.00 | $34883.00 | $23325.00 | $564415.00 | $262013.00 | $63000.00 | $113000.00 | $95000.00 | $158000.00 | $0.00 | $0.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $588129.00 | $748648.00 | $1.09M | $394748.00 | $1.69M | $1.16M | $2.43M | $2.53M | $6.79M | $8.17M | $7.55M | $3.48M | $5.85M | $13.62M |
| Free cash flow | $-9.30M | $-11.51M | $-15.54M | $-10.18M | $-14.61M | $12.50M | $-3.69M | $-19.40M | $-40.60M | $-71.00M | $-26.85M | $-30.84M | $-49.06M | $-51.46M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $1373.00 | — | — | — | $1.08M | — | $32.90M | $14.81M | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | $15.38M | — | — | — | — | — |